SCHEMBL2234570

SCHEMBL2234570

Clc1ccnc(Cl)n1.Clc1ncccn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.44
RPS6KA5 O75582 4/20 0.41
RPS6KA4 O75676 3/20 0.41
CCR1 P32246 3/20 0.34
CCR8 P51685 3/20 0.34
CCR5 P51681 2/20 0.34
NR4A2 P43354 1/20 0.34
CYP3A4 P08684 4/20 0.33
MAPT P10636 4/20 0.33
LMNA P02545 3/20 0.33
ALDH1A1 P00352 3/20 0.33
TSHR P16473 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
PMP22 Q01453 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
KDM4E B2RXH2 2/20 0.33
TP53 P04637 2/20 0.33
HSP90AA1 P07900 2/20 0.33
MMP9 P14780 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29483856 0.92
SCHEMBL63023 0.92
Fluoride SCHEMBL27460684 0.90
Pyrazine SCHEMBL23856033 0.85 RPS6KA5 (0.35) TDP1RPS6KA5RPS6KA4
Methyl Alcohol SCHEMBL17255950 0.85 TDP1 (0.39) TDP1RPS6KA5RPS6KA4CCR1CCR8
Cyanide SCHEMBL28136065 0.85 RPS6KA5 (0.35) TDP1RPS6KA5RPS6KA4
Pyridine SCHEMBL28152590 0.84 TDP1 (0.39) TDP1RPS6KA5RPS6KA4CCR1CCR8
SCHEMBL29236946 0.83 RPS6KA5 (0.38) TDP1RPS6KA5RPS6KA4
Pyrrole SCHEMBL6140688 0.82 RPS6KA5 (0.33) TDP1RPS6KA5RPS6KA4NR4A2
Toluene SCHEMBL28240238 0.81 LMNA (0.44) TDP1RPS6KA5RPS6KA4MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2531197-B1 SOLID STATE FORMS OF MACROCYCLIC KINASE INHIBITORS TRAGARA PHARMACEUTICALS INC (US) 2017-05-17 EP disclosed
US-9120815-B2 Solid state forms of macrocyclic kinase inhibitors TRAGARA PHARMACEUTICALS, INC. (US) 2015-09-01 US disclosed
US-20130150378-A1 SOLID STATE FORMS OF MACROCYCLIC KINASE INHIBITORS Cothera Bioscience, Inc. (KY) 2013-06-13 US disclosed
EP-2531197-A1 SOLID STATE FORMS OF MACROCYCLIC KINASE INHIBITORS Tragara Pharmaceuticals, Inc. (US) 2012-12-12 EP disclosed
WO-2011097525-A1 SOLID STATE FORMS OF MACROCYCLIC KINASE INHIBITORS TRAGARA PHARMACEUTICALS, INC. (US) 2011-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150378-A1 SOLID STATE FORMS OF MACROCYCLIC KINASE INHIBITORS MAP3K20, MAP3K15, MAP3K1 TDP1 1828/4885RPS6KA5 230/4885RPS6KA4 250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.